Cyclacel reports preliminary data from its phase 1/2 clinical trial of oral fadraciclib in patients with solid tumors and lymphoma at ena 2022

Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 prs in t-cell lymphoma patients daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 prs in t-cell lymphoma patients
CYCC Ratings Summary
CYCC Quant Ranking